Elranatamab vs Torutamig

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline

Elranatamab

Marketed by Pfizer

Approved in Multiple Myelomabispecific antibody (T-cell engager)
Weak signal

NCT05014412 · Phase 2 · completed

The study was nonrandomized, open-label, and single-arm, with all 85 treated participants receiving elranatamab and no placebo or active comparator. Its primary endpoint was a clinical safety outcome—grade 2 or higher cytokine release syndrome—and was reported in 12 participants, but the uncontrolled design provides limited evidence of treatment effectiveness.

Next expected readout: December 2026 · NCT06421675 (registry estimate)

Reported efficacy

Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2 (Parts 1 and 2: Cycle 1 (28 days)): Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2 (Parts 1 and 2: Cycle 1 (28 days)): All Participants 12 Participants (not_applicable)

Result source: NCT05014412

Torutamig

Developed by Biocad

Phase 3 in Multiple Myelomabispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT07742215 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointElranatamabTorutamig
PFS, median8b1000 mcg/kg SC · n 6NCT03269136
17 other results
  • 32.9 600 mcg/kg SC · n 6 · Phase 1 · secondary NCT03269136
  • 10.2 360 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 19.1 215 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 1 130 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 1 80 mcg/kg SC · n 6 · Phase 1 · secondary NCT03269136
  • 2.9 50 mcg/kg IV · n 6 · Phase 1 · secondary NCT03269136
  • 1.6 30 mcg/kg IV · n 5 · Phase 1 · secondary NCT03269136
  • 7.6 Q1W SC · n 7 · Phase 1 · secondary NCT03269136
  • 12.7 Q2W SC · n 13 · Phase 1 · secondary NCT03269136
  • 6.7 n 9 · Phase 1 · secondary NCT03269136
  • 10.4 n 15 · Phase 1 · secondary NCT03269136
  • 1.6 10 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 1.7 3 mcg/kg IV · n 3 · Phase 1 · secondary NCT03269136
  • 1.1 1 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 0.7 0.3 mcg/kg IV · n 3 · Phase 1 · secondary NCT03269136
  • 0.4 0.1 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 18.1 n 4 · Phase 1 · secondary NCT03269136
—Trial running · NCT07742215
OS, median32.9b600 mcg/kg SC · n 6NCT03269136
13 other results
  • 14 360 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 19.1 215 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 1.7 80 mcg/kg SC · n 6 · Phase 1 · secondary NCT03269136
  • 18 50 mcg/kg IV · n 6 · Phase 1 · secondary NCT03269136
  • 14.8 30 mcg/kg IV · n 5 · Phase 1 · secondary NCT03269136
  • 8.3 Q1W SC · n 7 · Phase 1 · secondary NCT03269136
  • 12.1 n 15 · Phase 1 · secondary NCT03269136
  • 16.2 10 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 8.1 3 mcg/kg IV · n 3 · Phase 1 · secondary NCT03269136
  • 11.2 1 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 8.4 0.3 mcg/kg IV · n 3 · Phase 1 · secondary NCT03269136
  • 8.2 0.1 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 31.3 n 4 · Phase 1 · secondary NCT03269136
—Trial running · NCT07742215
ORR53.3%bn 30NCT05228470
20 other results
—Trial running · NCT07742215
VGPR or better—Trial running · NCT05317416—Trial running · NCT07742215
MRD negativity—Trial running · NCT05317416—Trial running · NCT07742215

PFS, median

Elranatamab
8b1000 mcg/kg SC · n 6NCT03269136
17 other results
  • 32.9 600 mcg/kg SC · n 6 · Phase 1 · secondary NCT03269136
  • 10.2 360 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 19.1 215 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 1 130 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 1 80 mcg/kg SC · n 6 · Phase 1 · secondary NCT03269136
  • 2.9 50 mcg/kg IV · n 6 · Phase 1 · secondary NCT03269136
  • 1.6 30 mcg/kg IV · n 5 · Phase 1 · secondary NCT03269136
  • 7.6 Q1W SC · n 7 · Phase 1 · secondary NCT03269136
  • 12.7 Q2W SC · n 13 · Phase 1 · secondary NCT03269136
  • 6.7 n 9 · Phase 1 · secondary NCT03269136
  • 10.4 n 15 · Phase 1 · secondary NCT03269136
  • 1.6 10 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 1.7 3 mcg/kg IV · n 3 · Phase 1 · secondary NCT03269136
  • 1.1 1 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 0.7 0.3 mcg/kg IV · n 3 · Phase 1 · secondary NCT03269136
  • 0.4 0.1 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 18.1 n 4 · Phase 1 · secondary NCT03269136
Torutamig
—Trial running · NCT07742215

OS, median

Elranatamab
32.9b600 mcg/kg SC · n 6NCT03269136
13 other results
  • 14 360 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 19.1 215 mcg/kg SC · n 4 · Phase 1 · secondary NCT03269136
  • 1.7 80 mcg/kg SC · n 6 · Phase 1 · secondary NCT03269136
  • 18 50 mcg/kg IV · n 6 · Phase 1 · secondary NCT03269136
  • 14.8 30 mcg/kg IV · n 5 · Phase 1 · secondary NCT03269136
  • 8.3 Q1W SC · n 7 · Phase 1 · secondary NCT03269136
  • 12.1 n 15 · Phase 1 · secondary NCT03269136
  • 16.2 10 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 8.1 3 mcg/kg IV · n 3 · Phase 1 · secondary NCT03269136
  • 11.2 1 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 8.4 0.3 mcg/kg IV · n 3 · Phase 1 · secondary NCT03269136
  • 8.2 0.1 mcg/kg IV · n 2 · Phase 1 · secondary NCT03269136
  • 31.3 n 4 · Phase 1 · secondary NCT03269136
Torutamig
—Trial running · NCT07742215

ORR

Elranatamab
53.3%bn 30NCT05228470
20 other results
Torutamig
—Trial running · NCT07742215

VGPR or better

Elranatamab
—Trial running · NCT05317416
Torutamig
—Trial running · NCT07742215

MRD negativity

Elranatamab
—Trial running · NCT05317416
Torutamig
—Trial running · NCT07742215
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Torutamig: no structured comparison results are available for Multiple Myeloma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Elranatamab: 4 of 4 rows · Torutamig: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricElranatamab
Dropout rate
n/a: no completion milestonePart 2A: Dose Level 1a
NCT05014412 · Phase 2
show 22 more results
n/a: no completion milestonePart 2A: Dose Level 2
NCT05014412 · Phase 2
n/a: no completion milestonePhase 1b
NCT05228470 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePhase 2
NCT05228470 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone1000 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone130 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone80 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone50 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone30 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone10 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone0.3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone0.1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestoneQ1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestoneQ2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
n/a: no completion milestonePart 1C: PF-06863135 + Lenalidomid
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1D: PF-06863135 + Pomalidomid
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
—Part 2A: PF-06863135 SC
NCT03269136 · Phase 1 · registry result, not featured evidence
50%
NCT04798586 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—Part 2A: Dose Level 1a
NCT05014412 · Phase 2
show 22 more results
—Part 2A: Dose Level 2
NCT05014412 · Phase 2
—Phase 1b
NCT05228470 · Phase 2 · registry result, not featured evidence
—Phase 2
NCT05228470 · Phase 2 · registry result, not featured evidence
0%1000 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
33.3%600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
25%360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0%215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0%130 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0%80 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
33.3%50 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%30 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%10 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%0.3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%0.1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
14.3%Q1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0%Q2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0%Part 1C: PF-06863135 + Lenalidomid
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
11.1%Part 1D: PF-06863135 + Pomalidomid
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
—Part 2A: PF-06863135 SC
NCT03269136 · Phase 1 · registry result, not featured evidence
—
NCT04798586 · Phase 1 · registry result, not featured evidence
Serious AEs
91.7%Part 2A: Dose Level 1a
NCT05014412 · Phase 2
show 22 more results
72.7%Part 2A: Dose Level 2
NCT05014412 · Phase 2
75%Phase 1b
NCT05228470 · Phase 2 · registry result, not featured evidence
76.7%Phase 2
NCT05228470 · Phase 2 · registry result, not featured evidence
83.3%1000 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
66.7%600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
75%360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
75%215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
25%130 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
66.7%80 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
83.3%50 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
40%30 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%10 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
100%3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
33.3%0.3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0%0.1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
85.7%Q1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
69.2%Q2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
50%Part 1C: PF-06863135 + Lenalidomid
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
88.9%Part 1D: PF-06863135 + Pomalidomid
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
80%Part 2A: PF-06863135 SC
NCT03269136 · Phase 1 · registry result, not featured evidence
75%
NCT04798586 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
cytokine release syndrome 58.3%
decreased appetite 58.3%
fatigue 58.3%
NCT05014412 · Phase 2
show 22 more results
cytokine release syndrome 72.7%
fatigue 54.5%
neutropenia 54.5%
NCT05014412 · Phase 2
thrombocytopenia 100%
leukopenia 87.5%
neutropenia 87.5%
NCT05228470 · Phase 2 · registry result, not featured evidence
neutropenia 73.3%
anaemia 66.7%
covid-19 66.7%
NCT05228470 · Phase 2 · registry result, not featured evidence
1000 mcg/kg SC
lymphopenia 100%
anaemia 83.3%
injection site reaction 83.3%
NCT03269136 · Phase 1 · registry result, not featured evidence
600 mcg/kg SC
cytokine release syndrome 100%
injection site reaction 83.3%
lymphopenia 83.3%
NCT03269136 · Phase 1 · registry result, not featured evidence
360 mcg/kg SC
anaemia 100%
lymphopenia 100%
skin exfoliation 75%
NCT03269136 · Phase 1 · registry result, not featured evidence
215 mcg/kg SC
lymphopenia 100%
anaemia 75%
leukopenia 75%
NCT03269136 · Phase 1 · registry result, not featured evidence
130 mcg/kg SC
anaemia 75%
injection site reaction 75%
lymphopenia 75%
NCT03269136 · Phase 1 · registry result, not featured evidence
80 mcg/kg SC
thrombocytopenia 83.3%
anaemia 66.7%
lymphopenia 66.7%
NCT03269136 · Phase 1 · registry result, not featured evidence
50 mcg/kg IV
cytokine release syndrome 83.3%
thrombocytopenia 66.7%
anaemia 50%
NCT03269136 · Phase 1 · registry result, not featured evidence
30 mcg/kg IV
anaemia 80%
cytokine release syndrome 80%
fatigue 80%
NCT03269136 · Phase 1 · registry result, not featured evidence
10 mcg/kg IV
anaemia 100%
arthralgia 100%
back pain 50%
NCT03269136 · Phase 1 · registry result, not featured evidence
3 mcg/kg IV
productive cough 66.7%
thrombocytopenia 66.7%
anaemia 33.3%
NCT03269136 · Phase 1 · registry result, not featured evidence
1 mcg/kg IV
anaemia 50%
arthralgia 50%
aspartate aminotransferase increased 50%
NCT03269136 · Phase 1 · registry result, not featured evidence
0.3 mcg/kg IV
anaemia 66.7%
arthralgia 66.7%
alanine aminotransferase increased 33.3%
NCT03269136 · Phase 1 · registry result, not featured evidence
0.1 mcg/kg IV
anaemia 50%
aspartate aminotransferase increased 50%
hypomagnesaemia 50%
NCT03269136 · Phase 1 · registry result, not featured evidence
Q1W SC
anaemia 85.7%
cytokine release syndrome 85.7%
injection site reaction 85.7%
NCT03269136 · Phase 1 · registry result, not featured evidence
Q2W SC
cytokine release syndrome 84.6%
neutropenia 84.6%
thrombocytopenia 76.9%
NCT03269136 · Phase 1 · registry result, not featured evidence
arthralgia 100%
dry skin 100%
injection site reaction 100%
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
fatigue 77.8%
neutropenia 77.8%
diarrhoea 66.7%
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
neutropenia 66.7%
decreased appetite 46.7%
fatigue 46.7%
NCT03269136 · Phase 1 · registry result, not featured evidence
cytokine release syndrome 100%
neutropenia 75%
pneumonia 75%
NCT04798586 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Elranatamab

ORR 83.3% (n=6)1000 mcg/kg SC
responder rate · % of participants
No placebo or comparator arm
NCT03269136 · Phase 1 · registry result, not featured evidence
show 20 more results
66.7% (n=6)600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
75% (n=4)360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
50% (n=4)215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=4)130 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=6)80 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=6)50 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=5)30 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)10 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=3)3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=3)0.3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)0.1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
37.5% (n=8)
NCT05228470 · Phase 2 · registry result, not featured evidence
53.3% (n=30)
NCT05228470 · Phase 2 · registry result, not featured evidence
60% (n=15)
NCT03269136 · Phase 1 · registry result, not featured evidence
57.1% (n=7)Q1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
61.5% (n=13)Q2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
75% (n=4)
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
77.8% (n=9)
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
50% (n=4)
NCT04798586 · Phase 1 · registry result, not featured evidence
Time to Response 1.38 months1000 mcg/kg SC
time to event · months
No placebo or comparator arm
NCT03269136 · Phase 1 · registry result, not featured evidence · converted to months from 42 days as posted
show 11 more results
0.72 months*600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence · converted to months from 22 days as posted
0.72 months*360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence · converted to months from 22 days as posted
0.72 months*215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence · converted to months from 22 days as posted
2.04 months
NCT05228470 · Phase 2 · registry result, not featured evidence
1.45 months
NCT05228470 · Phase 2 · registry result, not featured evidence
1.28 months*Q1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence · converted to months from 39 days as posted
1.18 months*Q2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence · converted to months from 36 days as posted
1.71 months*
NCT03269136 · Phase 1 · registry result, not featured evidence · combination · converted to months from 52 days as posted
1.64 months*
NCT03269136 · Phase 1 · registry result, not featured evidence · combination · converted to months from 50 days as posted
1.31 months*
NCT03269136 · Phase 1 · registry result, not featured evidence · converted to months from 40 days as posted
1.396 months
NCT04798586 · Phase 1 · registry result, not featured evidence
Duration of Response NA months1000 mcg/kg SC
time to event · months
No placebo or comparator arm
NCT03269136 · Phase 1 · registry result, not featured evidence
show 9 more results
NA months600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
13.6 months360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
25.3 months215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
11.6 months
NCT03269136 · Phase 1 · registry result, not featured evidence
6.7 monthsQ1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
17.1 monthsQ2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
14.9 months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
8.3 months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
12.7 months
NCT04798586 · Phase 1 · registry result, not featured evidence
Complete 50% (n=6)1000 mcg/kg SC
responder rate · % of participants
No placebo or comparator arm
NCT03269136 · Phase 1 · registry result, not featured evidence
show 17 more results
50% (n=6)600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
25% (n=4)360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
50% (n=4)215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=4)130 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=6)80 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=6)50 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=5)30 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)10 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=3)3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=3)0.3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)0.1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
14.3% (n=7)Q1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
46.2% (n=13)Q2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
50% (n=4)
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
33.3% (n=9)
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
33.3% (n=15)
NCT03269136 · Phase 1 · registry result, not featured evidence
Duration of Complete Response NA months1000 mcg/kg SC
time to event · months
No placebo or comparator arm
NCT03269136 · Phase 1 · registry result, not featured evidence
show 8 more results
NA months600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
NA months360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
25.3 months215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
NA monthsQ1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
NA monthsQ2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
NA months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
NA months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
9.4 months
NCT03269136 · Phase 1 · registry result, not featured evidence
PFS 8 months1000 mcg/kg SC
time to event · months
No placebo or comparator arm
NCT03269136 · Phase 1 · registry result, not featured evidence
show 18 more results
32.9 months600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
10.2 months360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
19.1 months215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
1 months130 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
1 months80 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
2.9 months50 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
1.6 months30 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
1.6 months10 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
1.7 months3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
1.1 months1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0.7 months0.3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
0.4 months0.1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
7.6 monthsQ1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
12.7 monthsQ2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
18.1 months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
6.7 months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
10.4 months
NCT03269136 · Phase 1 · registry result, not featured evidence
NA months
NCT04798586 · Phase 1 · registry result, not featured evidence
Overall Survival NA months1000 mcg/kg SC
time to event · months
No placebo or comparator arm
NCT03269136 · Phase 1 · registry result, not featured evidence
show 18 more results
32.9 months600 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
14 months360 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
19.1 months215 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
NA months130 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
1.7 months80 mcg/kg SC
NCT03269136 · Phase 1 · registry result, not featured evidence
18 months50 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
14.8 months30 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
16.2 months10 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
8.1 months3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
11.2 months1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
8.4 months0.3 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
8.2 months0.1 mcg/kg IV
NCT03269136 · Phase 1 · registry result, not featured evidence
8.3 monthsQ1W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
NA monthsQ2W SC
NCT03269136 · Phase 1 · registry result, not featured evidence
31.3 months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
NA months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
12.1 months
NCT03269136 · Phase 1 · registry result, not featured evidence
NA months
NCT04798586 · Phase 1 · registry result, not featured evidence
MRD Negative 16.67% (n=6)1000 mcg/kg SC
responder rate · % of participants
No placebo or comparator arm
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
show 17 more results
16.67% (n=6)600 mcg/kg SC
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=4)360 mcg/kg SC
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
50% (n=4)215 mcg/kg SC
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=4)130 mcg/kg SC
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=6)80 mcg/kg SC
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=6)50 mcg/kg IV
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=5)30 mcg/kg IV
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)10 mcg/kg IV
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=3)3 mcg/kg IV
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)1 mcg/kg IV
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=3)0.3 mcg/kg IV
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
0% (n=2)0.1 mcg/kg IV
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
28.57% (n=7)Q1W SC
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
38.46% (n=13)Q2W SC
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence
25% (n=4)
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
0% (n=9)
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
33.33% (n=15)
10^-5 threshold MRD
NCT03269136 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elranatamab's landscape · Torutamig's landscape